A study presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Annual Meeting found that Janus kinase inhibitors (JAKi) for rheumatoid arthritis patients are associated with a higher risk of herpes zoster compared to biologic disease-modifying antirheumatic drugs (bDMARDs). However, the risk of other types of infections is similar or lower with JAKi compared to bDMARDs. The study involved data from the JAK-pot collaboration of 20 national registries. The analysis included over 50,000 exposures and found no significant differences in infection rates between JAKi, bDMARDs, and other modes of action (OMA) treatments, except for a higher risk of herpes zoster with JAKi.
Source link
Real-World RA Data Find JAK Inhibitor Infection Risk Is Low
